Osiris Therapeutics, Inc. (NASDAQ: OSIR)

DEFENDANT NAME: Osiris Therapeutics, Inc.
STOCK SYMBOL: NASDAQ: OSIR
CASE NUMBER:
COURT: U.S. District Court for the District of Maryland
PRACTICE AREA: Investor Fraud
STATUS: Active
CLASS PERIOD: May 12, 2014 to November 16, 2015
LEAD PLAINTIFF DEADLINE: January 22, 2016
DATE FILED:
COURT LOCATION:
KEY ATTORNEYS:
Reed R. Kathrein
RELATED DOCUMENTS:

Case documents will be listed here.

CONTACT:
510-725-3000 OSIR@hbsslaw.com

Hagens Berman alerts investors with losses over $50,000 of the January 22, 2016 lead plaintiff deadline in the securities fraud class action lawsuit filed against Osiris Therapeutics, Inc. (NASDAQ: OSIR).

If you suffered losses because of your purchase of Osiris securities between May 12, 2014 and November 20, 2015, contact Hagens Berman Partner Reed Kathrein, who is leading the firm’s investigation, by calling (510) 725-3000 or emailing OSIR@hbsslaw.com. The lawsuit was filed in the U.S. District Court for the District of Maryland and investors have until January 22, 2016 to move the court to act as lead plaintiff.

The complaint accuses the defendants of violations of the securities laws because Osiris failed to disclose during the Class Period that the Company overstated revenues from several contracts and failed to follow Generally Accepted Accounting Principles.

The news shocked investors when announced on November 16, 2015. Osiris disclosed that if they correctly recognized revenue for three contracts, it would result in substantial decreases in product revenues in 2014 and the first and second quarters of 2015.  In addition, Osiris announced that these restatements would result in the Company missing its revenue targets in three of the last four quarters. Following this news of an accounting restatement, Osiris shares fell, dropping $3.02, or 21.53%, to close at $10.97 on November 17, 2015.

If you lost more than $50,000 in your investments in Osiris securities between May 12, 2014 and November 20, 2015 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Whistleblowers: Persons with non-public information regarding Roadrunner should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at (510) 725-3000 or email OSIR@hbsslaw.com.


Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.

Back to all cases

Contact:

Please fill out the form below and we will get back to you as soon as we can.
 
*
*
*
*
*
*
*
*
*
*
*
Please Explain Your Potential Legal Claim *
File Upload *
*
*
*
*
 

Case videos

Case Gallery

Case Timeline

12/31/69: